Slow-Motion Trans Wreck
14th September 2022
In January of 2022, the San Francisco-based law firm Girard Sharp, which specializes in class action lawsuits, announced its investigation into the adverse effects of puberty blockers on transgender-identified children. These adverse effects can include low bone density, psychological problems, and potentially, per a July 2022 FDA warning label, pseudotumor cerebri, a condition which can cause brain swelling, headaches, nausea, double vision, and permanent loss of vision. Across the Atlantic, as of August 2022, the U.K.’s Tavistock Centre, a gender transition clinic, is expecting a class-action lawsuit from at least 1,000 families of children who were prescribed puberty blockers. Meanwhile, Sweden’s National Board of Health and Welfare released in February of 2022 new guidelines on transgender medicine, recommending that doctors not prescribe puberty blockers outside of “exceptional cases,” as their use is built on “uncertain science.” The reality that so-called “gender-affirming” medicine is not safe is now becoming too obvious to deny, and its implications could not be clearer: we are entering the long-overdue lawsuit phase of the transgender movement, and it is in lawsuits that this movement ends.